FDA Fentanyl Citrate Injection Shortage: Distributor Impact

FDA Drug Shortage Alert: Fentanyl Citrate Injection — Current Status & Distribution Impact

The FDA designated fentanyl citrate injection as in shortage as of January 2025, affecting multiple manufacturers' presentations across concentration strengths. Wholesale drug distributors holding DEA Schedule II licenses must implement allocation protocols and document customer notifications under both DSCSA transaction statement requirements and DEA controlled substance distribution recordkeeping rules.

Regulatory Context

Fentanyl citrate injection falls under DEA Schedule II classification (21 CFR 1308.12(b)(1)(iv)) and FDA pharmaceutical shortage monitoring under Section 506C of the FD&C Act. Wholesale distributors are subject to dual compliance obligations: DEA Form 222 (or CSOS electronic equivalent) transaction documentation per 21 CFR 1305, and DSCSA transaction information, transaction history, and transaction statement requirements per 21 USC 360eee-1(b)(1).

The FDA Drug Shortages Database, maintained under the FDA Safety and Innovation Act (FDASIA) Section 506C-1, provides manufacturer-level supply disruption data. When a medically necessary drug enters shortage status, wholesale distributors become critical nodes in allocation management — a function not explicitly codified in DSCSA but operationalized through existing DEA distribution controls and contractual customer relationships.

Current Shortage Status

As of January 20, 2025, the FDA lists fentanyl citrate injection across multiple National Drug Code (NDC) presentations as "currently in shortage." Affected concentrations include:

• 50 mcg/mL in 2 mL, 5 mL, 10 mL, 20 mL, and 50 mL vials
• Manufacturers reporting supply constraints: Hikma Pharmaceuticals, Fresenius Kabi, Pfizer (Hospira division)

The shortage does not affect fentanyl transdermal patches or oral formulations — only injectable presentations used in hospital and surgical settings. FDA has not issued a temporary importation allowance or compounding guidance as of this date, meaning domestic supply must be allocated within existing inventory.

Wholesale distributors typically maintain 30-60 day inventory positions on Schedule II injectables. With multiple manufacturers reporting constraints simultaneously, allocation decisions now fall to distributor procurement and compliance teams rather than routine automatic replenishment systems.

Distribution Obligations During Controlled Substance Shortages

Unlike non-controlled drug shortages, fentanyl citrate allocation triggers heightened documentation requirements:

DEA Recordkeeping: Each distribution must maintain the complete DEA Form 222 chain (or CSOS equivalent) from manufacturer through wholesale distributor to dispenser. Under 21 CFR 1304.21(a), these records must be maintained separately from non-controlled drug transaction records and made available for DEA inspection within 48 hours of request.

Customer Notification Protocols: While not explicitly required by statute, wholesale distributors operating under NABP accreditation standards (Criterion 2.5: Customer Service) must document notification to affected customers when allocation is implemented. This includes:

• Date allocation protocols were activated
• Methodology for allocation (pro-rata historical volume, clinical priority tier, etc.)
• Expected duration of constraint based on manufacturer communication

DSCSA Transaction Statements: The transaction statement accompanying each fentanyl citrate sale must remain accurate. If a distributor cannot fulfill standing orders due to shortage, the transaction history should not imply continuous availability. Distributors should avoid backdating transaction statements to mask allocation gaps — this creates ATP (Authorized Trading Partner) verification issues downstream.

Operational Impact for Wholesale Distributors

Distributors with hospital and surgical center customers face immediate allocation decisions. Fentanyl citrate injection is a medically necessary anesthetic used in:

• Post-surgical pain management
• ICU sedation protocols
• Epidural anesthesia procedures

Failure to allocate transparently creates downstream patient care risk and potential liability exposure if hospitals cannot access supply during critical procedures. However, over-allocation to single customers creates DEA audit risk if the distributor cannot demonstrate the allocation methodology was clinically justified rather than commercially preferential.

Distributors must balance three competing pressures: DEA compliance (no diversion risk from unusual ordering patterns), customer contractual obligations (fulfillment commitments in GPO or direct agreements), and FDA public health guidance (prioritize critical care facilities).

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — a baseline requirement for distributing any prescription drug, including Schedule II controlled substances. However, FDA registration alone does not indicate DEA Schedule II licensure, which is verified separately through state board of pharmacy records and is not yet included in ColdChainCheck's compliance scoring methodology.

The 63 entities holding NABP accreditation (formerly VAWD) represent the subset most likely to have documented allocation protocols in their quality management systems. NABP Criterion 2.5 requires accredited distributors to maintain written policies for product unavailability and customer communication. During controlled substance shortages, these policies become operationally critical — yet only 4.9% of tracked entities hold this accreditation.

The average compliance score of 51/100 reflects limited public visibility into distributors' operational readiness for shortage management. ColdChainCheck scores weight state licensure (25 pts), NABP accreditation (25 pts), FDA registration (20 pts), and enforcement history (30 pts). Entities in the "Fair" tier (919 distributors, score 41-60) typically hold licenses in fewer than 10 states and lack NABP accreditation — suggesting smaller regional operations that may rely on larger wholesalers for fentanyl citrate allocation rather than direct manufacturer relationships.

Operational Steps for QA and Procurement Teams

Verify your distributor's DEA Schedule II status: Use ColdChainCheck's directory to confirm FDA registration, then cross-reference with your state board of pharmacy for DEA licensure. FDA registration does not imply DEA authority to distribute controlled substances.

Request allocation methodology in writing: If your distributor activates allocation protocols, document their methodology. NABP-accredited distributors (searchable via the accreditation filter) are more likely to have written policies meeting audit standards.

Monitor for supply chain disruptions: ColdChainCheck tracks FDA enforcement actions and recalls. Distributors with recent warning letters (73 entities with recalls on record) may face additional scrutiny during DEA audits of controlled substance distribution patterns.

Check backup distributor compliance posture: If primary allocation falls short, secondary distributors must meet the same DEA and DSCSA requirements. Use compliance scores as a starting filter — entities scoring 70+ typically hold broader state licensure and NABP accreditation, indicating more robust compliance infrastructure.

ColdChainCheck continuously monitors FDA Drug Shortage Database updates. For related DSCSA and controlled substance distribution guidance, see the compliance guides section.

Disclaimer: This article provides informational analysis of publicly available FDA and DEA regulatory data. It is not legal or compliance advice. Wholesale distributors should consult qualified legal counsel and verify all regulatory obligations with the relevant federal and state authorities.

Update: FDA Sufentanil Shortage: Distributor Compliance Requirements

February 28, 2026

FDA Drug Shortage Alert: Sufentanil Citrate Injection — Distribution Impact & Compliance Obligations

FDA confirmed sufentanil citrate injection is in shortage as of January 2025, affecting multiple dosage strengths used in surgical anesthesia and critical care. Wholesale drug distributors holding DEA Schedule II controlled substance registrations must now implement allocation protocols, enhance diversion monitoring, and maintain detailed distribution records for this high-potency opioid during the shortage period.

Regulatory Background

Sufentanil citrate injection is classified as a Schedule II controlled substance under 21 CFR 1308.12(b)(1), subject to DEA diversion control requirements under the Controlled Substances Act. Drug shortages trigger additional compliance obligations under FDA's Drug Supply Chain Security Act (DSCSA) transaction documentation requirements (21 U.S.C. § 360eee-1) and DEA's suspicious order monitoring regulations (21 CFR 1301.74(b)). When a controlled substance reaches shortage status, distributors face heightened scrutiny from both agencies regarding allocation practices, distribution patterns, and transaction verification.

FDA maintains the Drug Shortages Database under authority granted by the FDA Safety and Innovation Act (FDASIA), which requires manufacturers to notify FDA of anticipated interruptions. The current sufentanil shortage stems from manufacturing delays at Fresenius Kabi USA, the primary supplier of 50 mcg/mL preservative-free formulations. Hikma Pharmaceuticals continues limited production but cannot meet national demand.

Key Details

FDA's shortage designation, published January 14, 2025, covers three sufentanil citrate injection presentations:

• 50 mcg/mL, 1 mL preservative-free ampule (NDC 63323-764-01) — discontinued by Fresenius Kabi
• 50 mcg/mL, 2 mL preservative-free ampule (NDC 63323-764-02) — intermittent availability from Hikma
• 50 mcg/mL, 5 mL preservative-free ampule (NDC 63323-764-05) — discontinued by Fresenius Kabi

Fresenius Kabi's January 9, 2025 notification to FDA cited API supply chain disruption and facility maintenance at its Grand Island, NY manufacturing site. The company projects restored production in Q3 2025 but has not committed to a specific resumption date. Hikma's New Jersey facility remains operational but is producing at 40% of normal output due to raw material constraints.

FDA has not approved temporary importation or compounding waivers for sufentanil. Health systems must use commercially available product from authorized distributors.

Distribution Impact and Compliance Obligations

Wholesale drug distributors face three immediate compliance requirements during this shortage:

Allocation documentation: Distributors implementing allocation programs for sufentanil must maintain written allocation policies documenting the methodology for distributing limited inventory. Under 21 CFR 205.50(g), records must demonstrate allocation decisions are not based on discriminatory factors. DEA expects distributors to justify allocation to accounts with established ordering histories, surgical case volume, or formulary commitments — not to prioritize buyers willing to pay premiums.

Enhanced suspicious order monitoring: The shortage creates diversion risk as gray market prices rise. Distributors must flag orders that exceed an account's historical sufentanil usage by more than 20%, orders from accounts without surgical/anesthesia capabilities, and orders requesting expedited delivery to new ship-to addresses. Under 21 CFR 1301.74(b), distributors must report suspicious orders to DEA within 14 days of detection.

DSCSA transaction compliance: Each sufentanil transaction during the shortage must include complete Transaction Information, Transaction History, and Transaction Statement (TI/TH/TS) as required under 21 U.S.C. § 360eee-1(b)(1). Distributors cannot abbreviate documentation or bypass ATP verification even during supply constraints. FDA increased DSCSA inspections of controlled substance distributors by 40% in 2024, with particular focus on high-diversion-risk products in shortage.

State boards of pharmacy in California, New York, and Ohio have issued additional guidance requiring distributors to report allocation methodologies and monthly sufentanil distribution volumes during the shortage period. Failure to file these state-level notifications can result in license suspension.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registration — the baseline requirement for distributing sufentanil citrate injection. However, only 63 entities carry NABP accreditation, which includes verification of controlled substance handling protocols and DEA compliance infrastructure. The average compliance score of 51/100 across the directory suggests many distributors operate with partial compliance visibility, creating risk during high-scrutiny shortage periods when DEA increases diversion monitoring.

The compliance score distribution reveals operational readiness gaps: while 28 entities scored in the "Excellent" tier (76-100 points) and 281 in the "Good" tier (61-75 points), 919 entities — 72% of the directory — fall into the "Fair" tier (41-60 points). These entities typically lack NABP accreditation, multi-state licensure coverage, or verified suspicious order monitoring programs. During a controlled substance shortage, distributors in the Fair tier face higher audit risk because they cannot quickly demonstrate allocation documentation or enhanced diversion controls to inspectors.

73 entities in the directory have at least one FDA recall, warning letter, or enforcement action on record. Any distributor with a prior controlled substance violation must implement heightened shortage protocols — DEA applies stricter scrutiny to repeat offenders during supply disruptions.

Practical Guidance for Compliance Teams

• Verify your sufentanil suppliers: Use the ColdChainCheck directory to confirm current FDA registration status and NABP accreditation for any distributor offering sufentanil during the shortage. Entities scoring below 50 lack multiple compliance signals — request allocation policy documentation and DEA suspicious order monitoring procedures before placing orders.

• Cross-reference state licensure: Sufentanil distribution requires active wholesale drug distributor licenses in both the ship-from and ship-to states. Check the state licensure tab in each entity's ColdChainCheck profile to verify coverage. Distributors operating on expired licenses in key states (California, New York, Texas, Ohio) cannot legally fulfill sufentanil orders even if FDA-registered.

• Review enforcement history: Distributors with prior DEA violations or FDA warning letters related to controlled substances appear in ColdChainCheck's enforcement signal data. During shortages, source from distributors with clean regulatory records — gray market sellers with compliance gaps create audit liability for the buyer under DSCSA transaction documentation rules.

• Monitor NABP accreditation status: The 63 NABP-accredited entities in ColdChainCheck's directory undergo annual audits of controlled substance handling. Prioritize these distributors for sufentanil sourcing during the shortage — NABP accreditation provides third-party verification of DEA compliance infrastructure.

ColdChainCheck tracks FDA drug shortage alerts, DEA enforcement actions, and state board of pharmacy guidance as compliance signals. See the regulatory guides section for coverage of DSCSA transaction requirements and suspicious order monitoring obligations.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal or compliance advice. Verify all regulatory requirements with the relevant state board of pharmacy, FDA, and DEA before making distribution decisions.